Abstract
In 1999, 30,000 people in the United States will be diagnosed with cancers of the kidney and renal pelvis (1). Although most cases are sporadic, populations at increased risk for developing renal cell carcinoma (RCC) include those with familial syndromes such as hereditary clear cell renal carcinoma, hereditary papillary renal carcinoma, and von Hippel-Lindau (VHL) syndrome, as well as patients with autosomal dominant polycystic kidney disease, tuberous sclerosis, and end-stage renal disease who develop acquired cystic disease of the kidney (2).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
